ABSTRACT
The LRRK2 G2019S pathogenic mutation causes LRRK2-associated Parkinson's disease (L2PD) with incomplete penetrance. LRRK2 non-manifesting carriers (L2NMC) are at PD high risk but predicting pheno-conversion is challenging given the lack of progression biomarkers. To investigate novel biomarkers for PD premotor stages, we performed a longitudinal microRNA (miRNA) assessment of serum samples from G2019S L2NMC followed-up over 8 years. Our cohort consisted of G2019S L2NMC stratified by dopamine transporter single-photon emission computed tomography (DaT-SPECT) into DaT-negative (n = 20) and DaT-positive L2NMC (n = 20), pheno-converted G2019S L2PD patients (n = 20), idiopathic PD (iPD) (n = 19), and controls (n = 40). We also screened a second cohort of L2PD patients (n = 19) and controls (n = 20) (Total n = 158). Compared to healthy controls, we identified eight deregulated miRNAs in DaT-negative L2NMC, six in DaT-positive L2NMC, and one in L2PD. Between groups, the highest miRNA differences, 24 candidate miRNAs, occurred between DaT-positive L2NMC and L2PD. Longitudinally, we found 11 common miRNAs with sustained variation in DaT-negative and DaT-positive L2NMCs compared to their baselines. Our study identifies novel miRNA alterations in premotor stages of PD co-occurring with progressive DaT-SPECT decline before motor manifestation, whose deregulation seems to attenuate after the diagnosis of L2PD. Moreover, we identified four miRNAs with relatively high discriminative ability (AUC = 0.82) between non-pheno-converted DaT-positive G2019S carriers and pheno-converted L2PD patients (miR-4505, miR-8069, miR-6125, and miR-451a), which hold potential as early progression biomarkers for PD.
ABSTRACT
El objetivo de este studio fue describer los hábitos de consumo de plantas medicinales de una muestra de pacientes atendidos durante el 2007 en un Centro de Atención Primaria de Barcelona (CAP Ciutat Meridiana). Se realizó un estudio descriptivo transversal mediante una encuesta llevada a cabo por los médicos de familia y las enfermeras del grupo de trabajo. Los resultados confirman la omisión del dato de consumo en la consulta, tanto por parte de los pacientes como del equipo sanitario: un 59,6% de los entrevistados manifestó que consumía plantas medicinales y un 74,8% de los consumidores no se lo había comentado al médico o enfermera, quienes, a su vez no habían preguntado acerca del posible consumo a un 89,8% de los entrevistados. A partir del dato de que un 58% de los consumidores tomaban a la vez medicación crónica, se calculó en un 18,8% la probabilidad de aparición de interacciones entre plantas y otros medicamentos (AU)
The aim of this study was to describe the medicinal plant consumption habits of a sample of the patients who attended a social security primary health care in Barcelona (CAP od Ciutat Meridiana) along 2007. A cross-sectional descriptive study was carried out by family doctors and nurses of the workgroup. The results confirm the missing of consumption data in the medical consultation, by both patients and practitioner. On one hand, 59,6% of the interviewed patients consume medicinal plants, and 74,8% of these did not mention it to their doctor. On the other hand, 89,6% of the doctos did not ask their patients if they consumed medicinal plants. Additionally, 58% of the patients that consumed medicinal plants, also followed a chronic drug treatment at the same time, allowing as to calculate a 18,8% of potential interactions (AU)
